vs

Side-by-side financial comparison of Acadian Asset Management Inc. (AAMI) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Acadian Asset Management Inc. is the larger business by last-quarter revenue ($172.2M vs $127.1M, roughly 1.4× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 2.6%). Over the past eight quarters, Acadian Asset Management Inc.'s revenue compounded faster (27.6% CAGR vs 20.8%).

United Asset Management was an American holding company headquartered in Boston, Massachusetts.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

AAMI vs ZLAB — Head-to-Head

Bigger by revenue
AAMI
AAMI
1.4× larger
AAMI
$172.2M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+14.5% gap
ZLAB
17.1%
2.6%
AAMI
Faster 2-yr revenue CAGR
AAMI
AAMI
Annualised
AAMI
27.6%
20.8%
ZLAB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AAMI
AAMI
ZLAB
ZLAB
Revenue
$172.2M
$127.1M
Net Profit
$34.7M
Gross Margin
51.0%
Operating Margin
33.3%
-54.6%
Net Margin
20.2%
Revenue YoY
2.6%
17.1%
Net Profit YoY
-18.4%
EPS (diluted)
$0.97
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$172.2M
$127.1M
Q3 25
$144.2M
$115.4M
Q2 25
$127.4M
$109.1M
Q1 25
$119.9M
$105.7M
Q4 24
$167.8M
$108.5M
Q3 24
$123.1M
$101.8M
Q2 24
$109.0M
$100.1M
Q1 24
$105.7M
$87.1M
Net Profit
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$34.7M
Q3 25
$15.1M
$-36.0M
Q2 25
$10.1M
$-40.7M
Q1 25
$20.1M
$-48.4M
Q4 24
$42.5M
Q3 24
$16.9M
$-41.7M
Q2 24
$11.0M
$-80.3M
Q1 24
$14.6M
$-53.5M
Gross Margin
AAMI
AAMI
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
AAMI
AAMI
ZLAB
ZLAB
Q4 25
33.3%
-54.6%
Q3 25
18.4%
-42.3%
Q2 25
12.7%
-50.3%
Q1 25
26.6%
-53.3%
Q4 24
38.7%
-62.6%
Q3 24
21.9%
-66.6%
Q2 24
18.9%
-76.0%
Q1 24
21.7%
-80.7%
Net Margin
AAMI
AAMI
ZLAB
ZLAB
Q4 25
20.2%
Q3 25
10.5%
-31.2%
Q2 25
7.9%
-37.3%
Q1 25
16.8%
-45.8%
Q4 24
25.3%
Q3 24
13.7%
-40.9%
Q2 24
10.1%
-80.2%
Q1 24
13.8%
-61.4%
EPS (diluted)
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$0.97
$-0.05
Q3 25
$0.42
$-0.03
Q2 25
$0.28
$-0.04
Q1 25
$0.54
$-0.04
Q4 24
$1.11
$-0.09
Q3 24
$0.45
$-0.04
Q2 24
$0.29
$-0.08
Q1 24
$0.37
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AAMI
AAMI
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$689.6M
Total DebtLower is stronger
$200.0M
Stockholders' EquityBook value
$715.5M
Total Assets
$677.0M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$689.6M
Q3 25
$717.2M
Q2 25
$732.2M
Q1 25
$757.3M
Q4 24
$779.7M
Q3 24
$616.1M
Q2 24
$630.0M
Q1 24
$650.8M
Total Debt
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$200.0M
Q3 25
Q2 25
Q1 25
Q4 24
$275.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$715.5M
Q3 25
$759.9M
Q2 25
$791.7M
Q1 25
$810.8M
Q4 24
$840.9M
Q3 24
$667.7M
Q2 24
$704.2M
Q1 24
$762.2M
Total Assets
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$677.0M
$1.2B
Q3 25
$751.4M
$1.2B
Q2 25
$672.3M
$1.2B
Q1 25
$677.3M
$1.2B
Q4 24
$703.2M
$1.2B
Q3 24
$555.2M
$985.3M
Q2 24
$533.1M
$987.4M
Q1 24
$544.9M
$988.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AAMI
AAMI
ZLAB
ZLAB
Operating Cash FlowLast quarter
$-2.4M
$-26.0M
Free Cash FlowOCF − Capex
$-26.7M
FCF MarginFCF / Revenue
-21.0%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
-0.07×
TTM Free Cash FlowTrailing 4 quarters
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$-2.4M
$-26.0M
Q3 25
$-23.9M
$-32.0M
Q2 25
$61.6M
$-31.0M
Q1 25
$-48.8M
$-61.7M
Q4 24
$55.8M
$-55.8M
Q3 24
$69.6M
$-26.8M
Q2 24
$45.7M
$-42.2M
Q1 24
$-40.4M
$-90.1M
Free Cash Flow
AAMI
AAMI
ZLAB
ZLAB
Q4 25
$-26.7M
Q3 25
$-35.0M
Q2 25
$-33.9M
Q1 25
$-63.2M
Q4 24
$-58.4M
Q3 24
$-28.2M
Q2 24
$-42.9M
Q1 24
$-91.1M
FCF Margin
AAMI
AAMI
ZLAB
ZLAB
Q4 25
-21.0%
Q3 25
-30.4%
Q2 25
-31.1%
Q1 25
-59.9%
Q4 24
-53.8%
Q3 24
-27.7%
Q2 24
-42.9%
Q1 24
-104.5%
Capex Intensity
AAMI
AAMI
ZLAB
ZLAB
Q4 25
0.5%
Q3 25
2.6%
Q2 25
2.6%
Q1 25
1.5%
Q4 24
2.4%
Q3 24
1.3%
Q2 24
0.7%
Q1 24
1.1%
Cash Conversion
AAMI
AAMI
ZLAB
ZLAB
Q4 25
-0.07×
Q3 25
-1.58×
Q2 25
6.10×
Q1 25
-2.43×
Q4 24
1.31×
Q3 24
4.12×
Q2 24
4.15×
Q1 24
-2.77×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AAMI
AAMI

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons